Biotechnology

Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies

February 11, 2021 7:15 AM

Hypertension program evaluating effectiveness of DehydraTECH-processed CBD now consists of three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / February 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces significant progress in its 2021 applied research and development (R&D) program with additional focus...

Read more

CB Scientific, Inc. (CBSC) and Shenzhen Semacare Medical Technology Co., Ltd. Announce Collaborative Partnership Agreement

February 11, 2021 7:00 AM

Companies to form a strategic partnership to collaborate on new monitoring solutions for growing international remote cardiac monitoring markets SHENZHEN, CHINA and ESCONDIDO, CA / ACCESSWIRE / February 11, 2021 / CB Scientific. Inc. (OTC PINK:CBSC)("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, is pleased to announce that it has entered into a collaborative...

Read more

RepliCel Closes First Tranche of Strategic Investment Commitment

February 10, 2021 6:00 AM

MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment Agreement VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the first tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share...

Read more

Medspresso Partners up with Zootly: South Africa's Leading Cannabis Destination

February 9, 2021 10:00 AM

CAPE TOWN, SA / ACCESSWIRE / February 9, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its MedspressoTm brand focused on creating premium African functional beverages: This past week MedspressoTm set the seal on its alliance with South African retailer: Zootly. The...

Read more

Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering

February 9, 2021 8:30 AM

IRVINE, CA / ACCESSWIRE / February 9, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its upsized underwritten public offering of units for gross proceeds of approximately $36 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company. The public offering is comprised of 5,142,856...

Read more

OPTEC International Adds Pandemic 10 Minute Rapid-Test Kits To PPE Distribution Network

February 9, 2021 8:00 AM

CARLSBAD, CA / ACCESSWIRE / February 9, 2021 / OPTEC International, Inc. (OTC PINK:OPTI), a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment (PPE), today announced the addition of Antigen & Antibody Rapid-Test Kits with highly accurate results in 10 Minutes to the company's PPE Inventory for global distribution. The Rapid-Test Kits are manufactured in the USA and comply with...

Read more

Applied UV Announces Acquisition of the Airocide(R) Technology Platform for Airborne Pathogen Reduction

February 9, 2021 6:00 AM

Developed with NASA as a patented pathogen killing technology Proprietary photocatalytic oxidation process thoroughly destroys viruses, bacteria, spores, and fungi as well as other carbon-based molecules Airocide® air disinfection technology compliments and expands the SteriLumen platform, together providing a more comprehensive solution for air and surface Accelerates the strategy to grow revenues through complimentary...

Read more

Apollo Endosurgery Announces CEO Transition

February 8, 2021 9:15 AM

Will Transition to Accomplished Commercial and Operational Medtech Veteran Charles Mckhann AUSTIN, TX / ACCESSWIRE / February 8, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today a planned CEO change. Effective March 1, 2021, Charles (Chas) McKhann will become CEO and a member of the Board of Directors....

Read more

RepliCel CEO Provides Corporate Update

February 8, 2021 6:00 AM

Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing  VANCOUVER, BC / ACCESSWIRE / February 8, 2021 / RepliCel Life Sciences Inc. (TSXV:RP)(OTC PINK:REPCF)(FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its Board and Management...

Read more

EastWest Bioscience Announces Grant of Options and Debt Settlement

February 5, 2021 9:55 AM

VANCOUVER, BC / ACCESSWIRE / February 5, 2021 / EastWest Bioscience (the "Company" or "EastWest") (TSXV:EAST) announces, subject to its stock option plan, the grant of 1,720,000 stock options to certain directors, officers, employees and consultants issued pursuant to the Company's stock option plan. The options vest over a 2 year period, are exercisable at a price of $0.05 per share and expire in February 2024. The shares issuable upon exercise...

Read more

Molecular Partners Reports Corporate Highlights from Q4 2020 and Key Financials for FY2020

February 5, 2021 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 5, 2021 / Molecular Partners AG (SIX:MOLN) Research & Development Highlights: Virology: Initiated and rapidly advanced COVID-19 antiviral program into the clinic; secured collaboration with Novartis for co-development of multi-specific candidates MP0420 (ensovibep) and MP0423, including options for global commercialization; terms included potential total cash consideration of CHF...

Read more

Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro

February 3, 2021 9:40 PM

New study shows that Molecular Partners' tri-specific antiviral DARPin® candidates, ensovibep (MP0420) and the Company's preclinical candidate, MP0423, remain therapeutically active against the known mutations of SARS-CoV-2 including those present in the United Kingdom (UK) and South Africa (SA) variants Phase 2/3 clinical studies of ensovibep planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 3,...

Read more

Experion Provides 2021 Outlook and will be Presenting at the Live Webcast Investor Conference Thursday, February 4, 2021

February 3, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / February 3, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to share a market update, outlook for 2021 and to announce Mr. Jarrett Malnarich, Experion's CEO will be presenting at the live webcast investor conference this Thursday, February 4, 2021. As we enter 2021, Experion and its brand, Citizen Stash, have now been serving the Canadian premium...

Read more

Dyadic to Present at ZAPI Stakeholders Virtual Meeting

February 3, 2021 8:30 AM

JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced that Ronen Tchelet, PhD, Dyadic's Chief Scientific...

Read more

GeneCentric Therapeutics Announces the Appointment of Philippe Chemla, PhD, MBA, as Chief Business Officer

February 3, 2021 8:00 AM

DURHAM, NC / ACCESSWIRE / February 3, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the appointment of Philippe Chemla, PhD, MBA, as Chief Business Officer. Dr. Chemla has extensive experience across multiple areas of life sciences research and development, with a focus on strategic collaborations and business development. "Philippe brings a strong track record of senior management and...

Read more

MJ Biotech, Inc., Delivers Samples of Covid-19 Rapid Test Kits to Multiple Buyers In Africa

February 3, 2021 7:00 AM

CHEYENNE, WY / ACCESSWIRE / February 3, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce, samples of the Covid-19 Rapid Test Kits have been shipped and will arrive this week in The Republic of Namibia. in Southern Africa. Our MJTV Africa sales representative, Invest Africa Global, LLC (IAG), is now expected to finalize the initial orders for the Covid-19 Rapid Test Kits. Having the samples delivered to the potential buyers...

Read more

Tetra Bio-Pharma Creates the ENJOUCA Business Unit

February 3, 2021 6:30 AM

OTTAWA, ON / ACCESSWIRE / February 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA™. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF™ can be commercialized as a...

Read more

Early Warning Report in Accordance with National Instrument 62-103

February 2, 2021 7:20 PM

PENTICTON, BC / ACCESSWIRE / February 2, 2021 / Ms. Ciska Asriel issues this press release pursuant to Part 3 - Early Warning Requirements of National Instrument 62-103 with respect to EastWest Bioscience Inc. ("EastWest") Ms. Ciska Asriel, the COO and CFO of EastWest has directly acquired 500,000 common shares by a series of purchases through the facilities of the TSX Venture Exchange at $0.05 per share on February 2, 2021 (the...

Read more

Edesa Biotech Receives C$14 million for COVID-19 Study

February 2, 2021 12:15 PM

TORONTO, ON / ACCESSWIRE / February 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The funding will also help fund certain pre-clinical research intended to...

Read more

Dyadic Enters Collaboration with TurtleTree Scientific to Develop Recombinant Protein Growth Factors

February 2, 2021 9:00 AM

JUPITER, FL / ACCESSWIRE / February 2, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced a fully funded collaboration with TurtleTree Scientific to...

Read more